Bisanzio D, Davis AE, Talbird SE, Van Effelterre T, Metz L, Mathieu VO, Brogan AJ. Individual-based modeling of Ebola outbreaks in the DRC to assess the impact of preventive vaccination strategies. Poster presented at the 8th International Conference on Infectious Disease Dynamics; November 30, 2021. Bologna, Italy.
Lucas A, Wilson M, Brogan AJ, Wasserman M, Jones D, Hilton B, Farkouh R. In small doses: missing the booster dose in a reduced pneumococcal conjugate vaccination schedule. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.
Davis A, Brogan AJ, Talbird S, Wild L, Flanagan D. The public health and economic impact of increased screening and immediate initiation of antiretroviral treatment for HIV-1 in the UK. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.
Talbird SE, Fulton J, La EM, Miao Z, Brogan A, Lewis S. Characteristics and costs of optimized background therapy for treatment of heavily treatment-experienced adults with multidrug-resistant HIV-1 in the US: a clinical trial analysis. Poster presented at the 22nd Annual International AIDS Conference; July 24, 2018. Amsterdam, The Netherlands.
Wasserman M, Lucas A, Wilson M, Farkouh R, Brogan A, Hilton B, Jones D. Dynamic transmission modeling to address infant pneumococcal conjugate vaccine schedule modifications. Poster presented at the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 16, 2018. Melbourne, Australia.
Talbird SE, Brogan AJ, La EH, Perard R. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in France and Spain. Poster presented at the Health Technology Assessment international; June 14, 2015. Oslo, Norway.
Wilkins E, Fisher M, Brogan AJ, Talbird SE. An analysis of cost and health outcomes associated with tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the United Kingdom. Poster presented at the 20th International AIDS Conference; July 20, 2014.
Younossi ZM, Gordon SC, Saab S, Ahmed A, Brogan A, Cure S. A decision-analytic Markov model to evaluate the health outcomes of sofosbuvir for previously untreated patients with chronic hepatitis C virus genotype 1 infection. Poster presented at the American Association for the Study of Liver Diseases; November 1, 2013.
Younossi ZM, Saab S, Gordon SC, Ahmed A, Brogan A, Cure S. Evaluation of long-term health outcomes associated with earlier versus later initiation of treatment in previously untreated patients with chronic hepatitis C virus genotype 1 infection. Poster presented at the Annual Meeting of the American Association for the Study of Liver Diseases; November 1, 2013.
Brennan VK, Talbird SE, Beard SM, Brogan AJ, Flanagan D, Delpech V, Bosanquet N, Fisher M. The public health and economic impact from earlier diagnosis and earlier antiretroviral treatment of HIV in the UK. Poster presented at the 14th European AIDS Conference/EACS; October 16, 2013.
Domingo P, Hill A, Gostkorzewicz J, Brogan A. Comparative cost-effectiveness analysis between darunavir/r and other protease inhibitors in the treatment of HIV-1 infection in naïve patients in Spain. Poster presented at the Third National GESIDA Congress; November 2011. Seville, Spain. doi: 10.1016 / j.eimc.2012.11.001
Antela A, Llibre JM, Lopez Bernaldo De Quiros JC, Portilla J, Gallois A, Campbell A, Penafiel J, Brogan AJ, Talbird SE. HIV Treatment Cost-Effectiveness Study Group. An economic model to assess the cost-effectiveness of early treatment initiation for people with HIV infection in Spain. Poster presented at the Third National GESIDA Congress; November 2011. Seville, Spain.
Deniz B, Brogan AJ, Miller JD, Talbird SE, Thompson J. Cost-effectiveness assessment of telaprevir combination treatment compared to pegylated-interferon + ribavirin alone in the management of chronic hepatitis C in patients who failed a prior pegylated-interferon + ribavirin treatment. Poster presented at the Annual Scientific Meeting of the American College of Gastroenterology; October 2011.
Aragãgo F, Vera J, Vaz Pinto I, Talbird SE, Brogan AJ. Economic evaluation of early antiretroviral treatment for HIV-1 infected individuals in Portugal. Poster presented at the 6th Annual Conference of the International AIDS Society; July 2011.
Brogan AJ, Miller JD, Talbird SE, Thompson J, Deniz B. Long-term clinical value of telaprevir for treatment of treatment-naïve and treatment-experienced patients with hepatitis C virus infection: projections using decision-analytic modeling. Poster presented at the 2011 Digestive Disease Week; May 9, 2011. Chicago, IL.
Smets E, Stoll M, Hill A, Soorapanth S, Donatz V, Brogan AJ. Comparative cost-efficacy analysis of darunavir/r and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in Germany. Poster presented at the 12th European AIDS Conference/EACS; November 2009.
Smets E, Soorapanth S, Brogan AJ, Mrus J. Cost-efficacy analysis of darunavir/r vs. lopinavir/r as a first-line HIV treatment in the United States. Poster presented at the 47th Annual Meeting of the Infectious Diseases Society of America; October 2009.
Bischof M, Brogan AJ, Talbird SE, Cavassini M, Bernasconi E, Furrer H. Cost-effectiveness of the first-line antiretroviral backbone therapies in combination with efavirenz in HIV-infected patients in Switzerland. Poster presented at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 2009. Cape Town, South Africa.
Brogan AJ, Everhard F, Talbird SE, Hutt E. Cost-effectiveness of tenofovir/emtricitabine in treatment naïve adults with HIV infection in the United States. Poster presented at the 21st Annual Meeting and Showcase of the American Managed Care Pharmacy; April 2009.
Brogan AJ, Everhard F, Talbird SE, Hutt E, Zimovetz E. NRTI backbone pairs for treatment-naïve adults with HIV infection: a UK economic evaluation. Poster presented at the 9th International Congress on Drug Therapy in HIV Infection; November 2008.
Brogan AJ, Everhard F, Talbird SE, Hutt E. Cost-effectiveness of tenofovir/emtricitabine compared with other NRTI pairs in treatment-naïve adults with HIV infection in the United States. Poster presented at the 9th International Congress on Drug Therapy in HIV Infection; November 2008.
Brogan AJ, Mauskopf JA, Martin S, Smets E. Cost-effectiveness of darunavir for treatment experienced adults with HIV infection in the US. Poster presented at the Annual Meeting of the Institute for Operations Research and Management Science; October 2008.
Graham CN, Borker R, Oppe M, Uyl-de Groot CA, Brogan AJ, Barber B. Cost-effectiveness of panitumumab plus best supportive care (BSC) compared with BSC alone in chemorefractory metastatic colorectal cancer (MCRC) patients (PTS) with wild-type (WT) KRAS tumor status in the Netherlands. Poster presented at the 33rd European Society for Medical Oncology (ESMO) Congress; September 2008.
Talbird SE, Brogan AJ, Winiarski AP, Sander B. The cost-effectiveness of treating influenza-like illness with oseltamivir in the US. Poster presented at the 42nd Midyear Clinical Meeting of the American Society of Health-System Pharmacists; December 2007.
Mauskopf J, Brogan AJ, Malmberg C, Hwang P. Cost-effectiveness of darunavir for the management of HIV-infected, treatment-experienced adults in Canada. Poster presented at the 2007 ISPOR 12th Annual International Meeting; May 22, 2007. Previously presented at the 16th Annual Canadian Conference on HIV/AIDS Research.
Brogan AJ, Mauskopf JA, Martin S, Smets E. Cost-effectiveness analysis of darunavir/r for HIV infection in treatment-experienced adults in the US: understanding the uncertainty in the estimates. Poster presented at the 2007 ISPOR 12th Annual International Meeting; May 2007. Arlington, VA.
Mauskopf J, Brogan AJ, Malmberg C, Hwang P. Cost-effectiveness of darunavir for the management of HIV-infected, treatment-experienced adults in Canada. Poster presented at the 16th Annual Canadian Conference on HIV/AIDS Research; April 29, 2007.
Mauskopf JA, Brogan AJ, Smets E, Martin S. Cost-effectiveness of darunavir (TMC114)/ritonavir compared with currently available protease inhibitors in treatment-experienced HIV patients. Poster presented at the 8th International Congress on Drug Therapy in HIV Infection; November 2006.
Zlateva GP, Javitt JC, Earnshaw SR, Pliel AM, Graham CN, Brogan AJ, Shah S, Adamis AP. Cost-effectiveness model for age-related macular degeneration: comparing early and late Macugen® treatment. Poster presented at the 2006 EURETINA Congress; May 21, 2006. Lisbon, Portugal. Previously presented at the 2005 ISPOR 8th Annual European Congress.
Javitt JC, Earnshaw SR, Graham CN, Brogan AJ, Zlateva GP, Pleil AM. Cost-effectiveness of Macugen versus no treatment in age-related macular degeneration patients. Poster presented at the Association for Research in Vision and Ophthalmology (ARVO) 2006 Annual Meeting; April 2006.
Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ. Cost-effectiveness model for age-related macular degeneration: comparing Macugen® to Visudyne®. Poster presented at the 2006 World Ophthalmology Congress; February 2006. Previously presented at the ISPOR 8th Annual European Congress.
Earnshaw SR, Javitt JC, Zlateva GP, Pleil AM, Graham CN, Brogan AJ, Shah S, Adamis AP. Cost-effectiveness model for age-related macular degeneration: comparing Macugen® to Visudyne®. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 10, 2005. Florence, Italy.
Ettinger B, Earnshaw SR, Brogan AJ, Graham CN, Amonkar MM, Baran R. Modeled cost impact of persistence with bisphosphonate therapy for women with postmenopausal osteoporosis. Poster presented at the Academy of Managed Care Pharmacy 17th Annual Meeting & Showcase; April 23, 2005.
Earnshaw SR, Brogan AJ, Graham CN, Amonkar MM, Baran R, Hebborn A. The impact of persistency on economic models for bisphosphonate therapy in osteoporosis. Poster presented at the 5th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; March 26, 2005. Rome, Italy.
Brogan AJ, Mauskopf JA, Quattek K, Jordan J. Lower resource use of 908/ritonavir compared to nelfinavir may be explained by better tolerability. Poster presented at the 42nd Annual Meeting of the Infectious Disease Society of America; October 2004.